Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Total Revenue | 2,773 | 3,250 | 2,840 | 2,882.80 | 3,586.86 |
Total Expenses | 3,103 | 3,478 | 3,266 | 3,224.84 | 4,033.41 |
Profit Before Tax | -624 | -411 | -568 | -342.04 | -446.55 |
Profit After Tax | -621 | -279 | -297 | -137.95 | -311.79 |
Operating Profit after Depreciation | -28 | 71 | -177 | -66.30 | -181.41 |
Particulars (in ₹ Cr.) | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Fixed Assets | 4,167 | 4,415 | 4,119 | 4,250.36 | 3,603.69 |
Total Non Current Assets | 5,475 | 5,654 | 5,349 | 5,749.08 | 5,029.66 |
Total Current Assets | 2,208 | 2,589 | 2,425 | 2,429.83 | 2,814.65 |
TOTAL ASSETS | 7,683 | 8,243 | 7,774 | 8,178.91 | 7,844.31 |
Total Shareholder's Fund | 3,354 | 3,849 | 3,376 | 2,671.67 | 2,674.80 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 219 | 153 | 413 | -287 | 648.96 |
Net Cash used in Investing Activities | -138 | -118 | -204 | 1,471 | -147.38 |
Net Cash used in Financing Activities | 334 | -315 | -71 | -1,171 | -679.58 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 1,195 | 1,139 | 1,410 | 1,028 | 933.08 |
Total Expenses | 1,603 | 1,417 | 1,594 | 1,509 | 1,416.76 |
Profit Before Tax | -422 | -513 | -184 | -623 | -483.68 |
Profit After Tax | -422 | -466 | -140 | -392 | -325.68 |
Operating Profit after Depreciation | -171 | -49 | 89 | -281 | -263.51 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 2,226 | 2,392 | 2,584 | 2,093 | 2,044.35 |
Total Non Current Assets | 3,089 | 3,257 | 3,410 | 3,056 | 3,152.96 |
Total Current Assets | 1,779 | 1,475 | 2,388 | 1,839 | 1,606.55 |
TOTAL ASSETS | 4,868 | 4,732 | 5,798 | 4,895 | 4,759.51 |
Total Shareholder's Fund | 1,796 | 1,753 | 2,212 | 1,606 | 994.62 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 188 | 71 | -93 | -563 | 221.51 |
Net Cash used in Investing Activities | -75 | -3 | -244 | 1,014 | -16.15 |
Net Cash used in Financing Activities | 346 | -236 | 430 | -480 | -273.97 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 809 | 739 | 700 | 701 | 753 |
Total Expenses | 699 | 648 | 803 | 664 | 681 |
Profit Before Tax | -9 | -6 | -180 | -87 | -35 |
Profit After Tax | -16 | -16 | -177 | -86 | -73 |
Operating Profit after Depreciation | 119 | 121 | -49 | 45 | 96 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 370 | 352 | 355 | 288 | 260 |
Total Expenses | 321 | 272 | 401 | 263 | 270 |
Profit Before Tax | -36 | 6 | -126 | -74 | -107 |
Profit After Tax | -36 | 6 | -126 | -74 | -107 |
Operating Profit after Depreciation | 60 | 107 | -22 | 30 | -4 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Wockhardt Ltd | ₹1,340.35 | ₹21,776.98 |
Sun Pharmaceuticals Industries Ltd | ₹1,761.80 | ₹4,22,714.84 |
Divis Laboratories Ltd | ₹5,818.40 | ₹1,54,460.24 |
Cipla Ltd | ₹1,427.30 | ₹1,15,270.75 |
Dr Reddys Laboratories Ltd | ₹1,288.45 | ₹1,07,511.36 |
Torrent Pharmaceuticals Ltd | ₹3,157.60 | ₹1,06,862.73 |
03 Jan 2025, 11:22 am
08 Nov 2024, 04:42 pm
07 Nov 2024, 02:38 pm
16 Oct 2024, 09:21 am
07 Oct 2024, 02:59 pm